CN118234485A - 亚微米颗粒 - Google Patents

亚微米颗粒 Download PDF

Info

Publication number
CN118234485A
CN118234485A CN202280055882.4A CN202280055882A CN118234485A CN 118234485 A CN118234485 A CN 118234485A CN 202280055882 A CN202280055882 A CN 202280055882A CN 118234485 A CN118234485 A CN 118234485A
Authority
CN
China
Prior art keywords
lnp
sarna
trehalose
lipid
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280055882.4A
Other languages
English (en)
Chinese (zh)
Inventor
陈荣军
刘旭晗
罗宾·沙托克
安娜·布莱克尼
刘一帆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College Of Technology Ltd
Original Assignee
Imperial College Of Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Of Technology Ltd filed Critical Imperial College Of Technology Ltd
Publication of CN118234485A publication Critical patent/CN118234485A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280055882.4A 2021-06-14 2022-06-14 亚微米颗粒 Pending CN118234485A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108444.7A GB202108444D0 (en) 2021-06-14 2021-06-14 Sub-micron particle
GB2108444.7 2021-06-14
PCT/GB2022/051493 WO2022263808A1 (en) 2021-06-14 2022-06-14 Sub-micron particle

Publications (1)

Publication Number Publication Date
CN118234485A true CN118234485A (zh) 2024-06-21

Family

ID=76954481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280055882.4A Pending CN118234485A (zh) 2021-06-14 2022-06-14 亚微米颗粒

Country Status (6)

Country Link
US (1) US20240315981A1 (https=)
EP (1) EP4355303A1 (https=)
JP (1) JP2024523304A (https=)
CN (1) CN118234485A (https=)
GB (1) GB202108444D0 (https=)
WO (1) WO2022263808A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116004728A (zh) * 2021-10-21 2023-04-25 深圳大学总医院 一种聚合物包裹的脂质纳米粒及其制备方法、药物制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4023249T3 (pl) * 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
SG11201802073YA (en) * 2015-09-15 2018-04-27 Samyang Biopharmaceuticals Pharmaceutical composition containing anionic drug, and preparation method therefor
WO2017218704A1 (en) * 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
KR102259513B1 (ko) * 2017-11-16 2021-06-02 주식회사 삼양홀딩스 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
CA3146675A1 (en) * 2019-07-23 2021-01-28 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making
US20210330597A1 (en) * 2020-04-27 2021-10-28 New Jersey Institute Of Technology Nanoparticle Depot For Controlled And Sustained Gene Delivery

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116004728A (zh) * 2021-10-21 2023-04-25 深圳大学总医院 一种聚合物包裹的脂质纳米粒及其制备方法、药物制剂
CN116004728B (zh) * 2021-10-21 2025-02-28 深圳大学总医院 一种聚合物包裹的脂质纳米粒及其制备方法、药物制剂

Also Published As

Publication number Publication date
GB202108444D0 (en) 2021-07-28
JP2024523304A (ja) 2024-06-28
EP4355303A1 (en) 2024-04-24
US20240315981A1 (en) 2024-09-26
WO2022263808A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
Riccardi et al. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field
Li et al. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape
Machtakova et al. Polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapeutic agents
Soltani et al. Synthetic and biological vesicular nano-carriers designed for gene delivery
JP6214004B2 (ja) ナノ送達システム
JP6608996B2 (ja) 異なる医薬品の制御送達のためのビヒクル
Toy et al. Engineering nanoparticles to overcome barriers to immunotherapy
Gao et al. pH-responsive nanoparticles for drug delivery
CN104428005B (zh) 用于反义寡核苷酸递送的脂质纳米颗粒组合物
Cai et al. Highly efficient and safe delivery of VEGF siRNA by bioreducible fluorinated peptide dendrimers for cancer therapy
US11090367B2 (en) Restoration of tumor suppression using mRNA-based delivery system
Yang et al. Bioresponsive chimaeric nanopolymersomes enable targeted and efficacious protein therapy for human lung cancers in vivo
KR20160085794A (ko) 면역요법용 모듈러 입자
EP2898894A1 (en) Nano-in-micro particles for intradermal delivery
Sinsinbar et al. Amphiphilic block copolymer nanostructures as a tunable delivery platform: perspective and framework for the future drug product development
CN103566379A (zh) 一种“胞内触发”式还原敏感型药物联合基因靶向共传递体的制备及应用
Chauhan et al. Recent advances in liposome
US20250177301A1 (en) Triplex nanoparticles
US20260034202A1 (en) Payload delivery system
Giri Chitosan based nanoparticulate system for controlled delivery of biological macromolecules
CN116004728B (zh) 一种聚合物包裹的脂质纳米粒及其制备方法、药物制剂
CN118234485A (zh) 亚微米颗粒
Jin et al. Activity Relationship of Poly (ethylenimine)-Based Liposomes as Group A Streptococcus Vaccine Delivery Systems
Hartmeier et al. Immune cells activating biotin-decorated PLGA protein carrier
Gu et al. Engineering Delivery Technologies for Optimizing mRNA Vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination